Generation of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory B lymphocytes
Authors:
- Chi MaCMChi Ma
- Yanlai LuYLYanlai Lu
- Xu JiXJXu Ji
- Yongsheng PangYPYongsheng Pang
- Fang HuaFHFang Hua
- Lianxian CuiLCLianxian Cui
- Denian BaDBDenian Ba
- Wei HeWHWei He
- 5 August 2013
- journal article
- Published by Springer Nature in Cellular & Molecular Immunology
- Vol. 10 (5) , 403-412
Abstract
The 2009 H1N1 influenza pandemic demonstrated the significance of a global health threat to human beings. Although pandemic H1N1 vaccines have been rapidly developed, passive serotherapy may offer superior immediate protection against infections in children, the elderly and immune-compromised patients during an influenza pandemic. Here, we applied a novel strategy based on Epstein-Barr virus (EBV)-immortalized peripheral blood memory B cells to screen high viral neutralizing monoclonal antibodies (MAbs) from individuals vaccinated with the 2009 pandemic H1N1 vaccine PANFLU.1. Through a massive screen of 13 090 immortalized memory B-cell clones from three selected vaccinees, seven MAbs were identified with both high viral neutralizing capacities and hemagglutination inhibition (HAI) activities against the 2009 pandemic H1N1 viruses. These MAbs may have important clinical implications for passive serotherapy treatments of infected patients with severe respiratory syndrome, especially children, the elderly and immunodeficient individuals. Our successful strategy for generating high-affinity MAbs from EBV-immortalized peripheral blood memory B cells may also be applicable to other infectious or autoimmune diseases.Keywords
This publication has 41 references indexed in Scilit:
- Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cellsProceedings of the National Academy of Sciences, 2012
- Broadly neutralizing antibodies against influenza virus and prospects for universal therapiesCurrent Opinion in Virology, 2012
- Serologic cross-reactivity among humans and birds infected with highly pathogenic avian influenza A subtype H5N1 viruses in ChinaImmunology Letters, 2010
- Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trialThe Lancet, 2010
- Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza VirusNew England Journal of Medicine, 2009
- Structural and functional bases for broad-spectrum neutralization of avian and human influenza A virusesNature Structural & Molecular Biology, 2009
- Neutralizing antibodies derived from the B cells of 1918 influenza pandemic survivorsNature, 2008
- An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirusNature Medicine, 2004
- Phage antibodies: filamentous phage displaying antibody variable domainsNature, 1990
- Replacing the complementarity-determining regions in a human antibody with those from a mouseNature, 1986